• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Phase 3 Kidney Data Might Change The Case For Investing In Mineralys Therapeutics (MLYS)

    Simply Wall St·10/26/2026 21:33:36
    Listen to the news
    • Mineralys Therapeutics reported new Phase 3 data showing lorundrostat produced statistically significant reductions in systolic blood pressure and albuminuria in patients with and without chronic kidney disease in the Launch HTN trial presented at ASN Kidney Week 2026.
    • The similar blood pressure effect in chronic kidney disease and non chronic kidney disease patients, alongside a 52% cut in albuminuria versus placebo, indicates lorundrostat may address a broad uncontrolled hypertension population that often overlaps with high cost renal complications.
    • We will monitor how Mineralys Therapeutics' investment narrative develops as additional data on lorundrostat’s effects on blood pressure and albuminuria become available.

    Look beyond Mineralys Therapeutics and compare lorundrostat’s story with other late-stage healthcare plays using our curated list of 34 healthcare AI stocks

    Mineralys Therapeutics Investment Narrative Recap

    To own Mineralys Therapeutics, you need to believe lorundrostat can move from successful trials into an approved product for uncontrolled and resistant hypertension, and then potentially into related cardiorenal conditions. The fresh Launch HTN data reinforces that core thesis, since it speaks directly to blood pressure reduction and kidney health, which sit at the center of the program.

    The key near term catalyst remains progress toward an NDA filing and regulatory review for hypertension, rather than this single data cut. The biggest current risk still sits with approval timing, class competition in aldosterone synthase inhibitors, and the cash burn from building out commercial infrastructure while reporting losses and having no product revenue.

    The most relevant new development is the Launch HTN Phase 3 readout presented at ASN Kidney Week 2026. For you as a shareholder, the similar blood pressure effect in chronic kidney disease and non chronic kidney disease patients, alongside a 52% reduction in albuminuria versus placebo, gives more clinical depth to the lorundrostat story in a high risk population.

    This dataset matters for catalysts because it supports the idea that lorundrostat could address uncontrolled hypertension where kidney disease is common, which aligns with longer term label expansion goals. It also ties directly into existing risks. Any future regulatory request for extra data, or stronger competing aldosterone synthase data, could still reshape how much value this trial ultimately adds.

    Mineralys Therapeutics' narrative projects US$467.2 million revenue and US$16.6 million earnings by 2029. This implies a shift from earnings of a US$349.6 million loss today to the forecast consensus, which is an earnings increase of about US$366 million over that period.

    Uncover why Mineralys Therapeutics' fair value indicates a 136% potential upside to its current price, a discount that could narrow quickly once expectations reset.

    NasdaqGS:MLYS 1-Year Stock Price Chart
    NasdaqGS:MLYS 1-Year Stock Price Chart

    Exploring Other Perspectives

    You just saw fresh kidney data for Mineralys Therapeutics, yet the lowest analysts were more focused on payer pushback. Their pre news view leaned on tighter third and fourth line access and forecast only US$192.9 million revenue and US$33.2 million earnings by 2029. That gap shows how sharply opinions can differ, so it pays to explore a range of expectations.

    Explore 2 other Mineralys Therapeutics fair value estimates, including one that suggests it could be worth just $46.33!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Mineralys Therapeutics?

    If you want to stress test the lorundrostat story against other opportunities, it helps to line Mineralys Therapeutics up next to a broader watchlist built from clear financial filters.

    • If you prefer to focus on stability and downside protection first, then upside second, and want a starting point built around balance sheet strength, cash, and low leverage, take a look at our list of solid balance sheet and fundamentals (24 results).
    • If you are hunting for companies where price and fundamentals look out of sync based on cash generation and financial quality, use the curated 28 high quality undervalued stocks as a practical shortlist.
    • For readers who like to fish where fewer people are looking and want financially sound opportunities that attract less headline attention, our hand picked 21 high quality undiscovered gems can help surface fresh ideas.